Production (Stage)
Arrowhead Pharmaceuticals, Inc.
ARWR
$15.13
-$0.26-1.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 69.42% | -115.53% | -192.04% | -197.41% | -213.43% |
| Total Depreciation and Amortization | 32.68% | 39.10% | 48.84% | 54.32% | 50.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.84% | 11.95% | 2.78% | -4.02% | -21.42% |
| Change in Net Operating Assets | -34.06% | 1,021.02% | 148.68% | 160.95% | 148.58% |
| Cash from Operations | 123.80% | -150.38% | -200.77% | -78.73% | -4.98% |
| Capital Expenditure | 75.83% | 61.10% | 19.96% | -24.42% | -96.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,806.70% | -228.07% | -445.74% | -73.89% | -66.74% |
| Cash from Investing | -204.79% | -926.28% | -336.87% | -84.71% | -863.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -43.36% | 15,644.21% | 14,038.68% | 13,902.33% | 16,873.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -81.25% | -80.00% | -100.00% |
| Cash from Financing | 27.60% | 32,366.73% | 244.01% | 90.55% | 38.54% |
| Foreign Exchange rate Adjustments | 2,205.70% | 6,918.97% | 3,540.16% | 105.15% | 170.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 899.52% | 97.00% | -384.34% | -5.37% | -114.94% |